Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Ocrevus in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
2025-524164-37-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Roche. Primary endpoint: Cmax and AUCtau after first SC injection. Planned start Jun 2026; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2025-524164-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524164-37-00.